Browse studies
Find your next paid study
4 recruiting studies matching your filters
NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors
Background: All childhood cancers are rare, but some are called very rare. Very rare cancers are diagnosed in 2 or fewer out of 1 million people each year. Re…
Very Rare TumorsVery Rare CancersOther Solid Tumors+2 more
Estimated
~$10 – $675
National Cancer Institute (NCI)NCT07489378
Phase 1
An Open-label, Phase 1, Multicentre Platform Study to Evaluate the Safety and Preliminary Anti-tumour Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Participants With Advanced Malignancies That Are Positive for the TP53 R175H Mutation
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP5…
Non-small Cell Lung CancerHead and Neck Squamous Cell CarcinomaColorectal Carcinoma+5 more
Estimated
~$10 – $7,500
AstraZenecaNCT05877599
Phase 2
A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement
The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with previously treated, unresectable, locally…
FGFR2 Gene Fusion/RearrangementOther Solid Tumors, Adult
Estimated
~$10 – $8,750
Elevar TherapeuticsNCT07359820
Phase 1
A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harb…
Metastatic Uveal MelanomaCutaneous MelanomaColorectal Cancer+1 more
Estimated
~$10 – $8,750
IDEAYA BiosciencesNCT03947385